Navigation Links
Hundreds of alterations and potential drug targets to starve cancer tumors identified
Date:4/21/2013

Right now we have something like a static road map. We know where the streets are, but we don't know how traffic flows through the streets and intersections," said Jie Hu, PhD, a postdoctoral researcher at Columbia and first author of the study. "What researchers need is something similar to Google Traffic, which shows the flow and dynamic changes in car traffic."

Drs. Hu and Vitkup's study is an important step toward achieving this dynamic view of cancer metabolism. Notably, the researchers found that the tumor-induced expression changes are significantly different across diverse tumors. Although some metabolic changessuch as an increase in nucleotide biosynthesis and glycolysisappear to be more frequent across tumors, others, such as changes in oxidation phosphorylation, are heterogeneous.

"Our study clearly demonstrates that there are no single and universal changes in cancer metabolism," said Matthew Vander Heiden, MD, PhD, assistant professor at MIT, and a co-author of the paper. "That means that to understand transformation in cancer metabolism, researchers will need to consider how different tumor types adapt their metabolism to meet their specific needs."

The researchers also found that expression changes can mimic or cooperate with cancer mutations to drive tumor formation. A notable example is the enzyme isocitrate dehydrogenase. In several cancers, such as glioblastoma and acute myeloid leukemia, mutations in this enzyme are known to produce a specific metabolite2-hydroxyglutaratethat promotes tumor growth. The Columbia team found that isocitrate dehydrogenase expression significantly increases in tumors with the recurrent mutations. Such an overexpression may create an efficient enzymatic factory for overproduction of 2-hydroxyglutarate.

The analysis also led the researchers to an interesting finding in colon cancer. In several other cancers, mutations in two enzymessuccinate dehydrogenase and fumarate hydratasecan pro
'/>"/>

Contact: Karin Eskenazi
ket2116@cumc.columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Hundreds of random mutations in leukemia linked to aging, not cancer
2. Physicians at Pain Care Bring Hope to Hundreds of Pain Management Patients Who Previously Had None Through Use of a New Procedure Called Spinal Cord Stimulation
3. High-throughput sequencing shows potentially hundreds of gene mutations related to autism
4. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
5. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
6. Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers
7. Study identifies potential treatment for lethal childhood leukemia
8. McMaster researchers find potential for new uses of old drug
9. Army researcher develops potential vaccine carrier
10. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
11. New study of NIH funding allocations suggests potential efficiency gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 This Latest Guidebook for Conducting ... (2014 Edition) not only provided a comprehensive and thorough ... for imported drug registration but also introduced the practical ... guide you to use the Chinese trial venues to ... world step by step. , The audiences of this ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The ... (SQL, Nosql), Software (Database Application Builder, Data Scaling ... Models (Iaas, Paas, Dbaas) and Service Models (Public ... & Organization Size (Small And Medium, Large) - ... and segments the global cloud database and DBaaS ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Mortality rates increase due to extreme heat and cold 2Health News:CRN International Names New Director to Lead Client Services Department 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4
... state Health Directorate officials have confirmed that there has ... fever in about 29// villages of Nasik district. Around ... have been hospitalized. ,Malegon was the worst ... were sent to the National Institute of Virology (NIV), ...
... physician from Philadelphia has come out with a ... from arthritis. The technique when used will ease ... ,Interventional radiologist Kevin Baskin of Children's Hospital ... ankle joint of juvenile arthritis patients at the ...
... Pakistan's 155 million population carries the deadly hepatitis virus, ... ,"Hepatitis B and C is a time bomb ... to control it," said the president of the Pakistan ... 2006 report. ,The association represents medical practitioners ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... covering the provinces of Luanda, Bengo, Benguela, and Kwanza Norte. ... 13, the number of reported cases has risen to 2,026 ... Sunday WHO representative, Angola Fatoumata Diallo handed over 7 ... of Health Jose Van- Dunem. ,The National Laboratory ...
... showed that ROZEREM? (ramelteon) could be used for treating people ... reduce the time to fall asleep in adults significantly. // ... showed no signs of recurring or withdrawal effects. ... 8 mg of ROZEREM experienced at least a 50 percent ...
Cached Medicine News:Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 2Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 3Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 4
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first,natural compound to ... on stroke,recovery starting in the acute stage. ... trial to evaluate the efficacy of NeuroAid(TM) in ... with treatment starting within 48 hours of a ...
... 26 Rcadia Medical Imaging, Ltd.,developer of novel ... Food and Drug Administration (FDA) clearance to market,its ... triaging patients for,coronary artery disease (CAD). The new ... human intervention and automatic detection of,pathologies in the ...
Cached Medicine Technology:International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 2International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 3International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 4Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance 2
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: